Oct 2026· Medicine Advances· 0 citations· 79 references
TL;DR
This review supports the identification of novel therapeutic agents for eliminating drug‐resistant microorganisms by supporting the identification of novel therapeutic agents for eliminating drug‐resistant microorganisms.
Abstract
Rising multidrug resistance demands novel antimicrobials. Lantibiotics are ribosomally synthesized peptides with unique post‐translational modifications (including lanthionine) that confer potent bactericidal activity against Gram‐positive species. Their membrane‐disruptive and cellular inhibitory mechanisms make them promising candidates for next‐generation antibiotics to combat escalating antibiotic resistance. Lantibiotics exhibit a synergistic dual mode of action through binding to lipid II, a conserved peptidoglycan precursor essential for bacterial cell wall synthesis. This interaction inhibits peptidoglycan assembly and compromises the integrity of the cell wall, causing the cytoplasmic membranes to develop lipid II‐mediated pores, which result in ion leakage, membrane depolarization, and rapid bacterial death. Compared with single‐target antimicrobial drugs, the interdependence of these processes in lantibiotics provides a significant advantage against drug‐resistant bacteria by lowering the likelihood of resistance development. Naturally occurring lantibiotics from bacteria such as
Lactococcus
and
Streptomyces
have gained attention for therapeutic and preservation uses. This review summarizes their types, sources, structures, functions, variants, and potential applications in combating antibiotic‐resistant bacteria. Although progress is limited by pharmacokinetic and spectrum challenges, modifying natural lantibiotic scaffolds offers validated mechanisms, established efficacy, and accessible bioengineering routes for antibacterial development. In contrast,
de novo
drug design involves higher translational risk and complexity but enables rational creation of agents with improved stability, resistance profiles, and potential activity against Gram‐negative bacteria. This review supports the identification of novel therapeutic agents for eliminating drug‐resistant microorganisms.
The growing occurrence of antimicrobial resistance represents a major challenge to global healthcare and necessitates the development of novel therapeutic agents capable of overcoming multidrug-resistant (MDR) pathogens. Gramicidin S (GS), a cyclic decapeptide antibiotic has attracted renewed interest as a promising te...
T. S. Shkuratova, Daria V. Andreeva, A. Tikhomirov et al.· Future Medicinal Chemistry· 0 citations
Peptoids are a new class of peptidomimetics that mimic the structure of AMPs, overcoming several of these drawbacks through resistance to proteolysis and efficient, low-cost synthesis of short sequences.
Ghayah Bahatheg, T. Ibisanmi, David Stc Black et al.· RSC Advances· 1 citation
Given the surge in antibiotic resistance, antimicrobial peptides have emerged as promising alternatives to conventional antibiotics; however, their therapeutic potential remains hindered by proteolytic instability and insufficient potency. Herein, we integrated an anti-proteolytic Arg-Pro scaffold with N-terminal fatty...
Jia-Jun Wang, Hao-Ran Xu, Yu Sun et al.· Cell Chemical Biology· 0 citations
Over the years, many antibiotics have been developed, but most have become less effective due to antimicrobial resistance, especially those targeting enzymatic pathways. This growing resistance poses a serious global health threat. It is now recognized that physically disrupting bacterial cell membranes is less prone t...
Diletta Bergamo, Katarina Cirnski, Mathias Müsken et al.· Journal of Medicinal Chemist...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.